Corporate Performance     

Published: November 30, 2024
Updated: November 30, 2024

Evexia Lifecare Ltd

Excellent earnings for Q2FY25: Revenue spurts 162.61% YoY

Evexia Lifecare Ltd. (BSE: 524444), engaged in the trading of pharmaceuticals, chemicals, manufacturing of intermediates, agricultural produce and various other products of consumer goods, has announced its earnings for the quarter and half year ended 30 September 2024.

For quarter ended 30 September 2024, revenue from operations grew by 169.61% from Rs. 1065.04 Lakhs in Q2FY24 to Rs. 2796.91 Lakhs in Q2FY25. EBITDA increased to Rs. 113.74 Lakhs in Q2FY25, from Rs. 43.09 Lakhs in Q1FY25. PAT jumped 200% QoQ, from Rs. 24.12 Lakhs in Q1FY25 to Rs. 72.60 Lakhs in Q2FY25.

For half year ended 30 September 2024, revenue from operations grew by 99.43% from Rs. 2466.92 Lakhs in H1FY24 to Rs. 4919.70 Lakhs in H1FY25. EBITDA increased to Rs. 156.83 Lakhs in H1FY25. PAT increased to Rs. 97.71 Lakhs in H1FY25.

Recently, the company announced that it has executed Term sheet with Diponed Bio Private Limited for its intention to subscribe on preferential basis 18,600 fresh fully paid up equity shares. Upon completion of the issuance and allotment of the Subscription Shares, the Evexia shall hold 65% of the post issue share capital of the Company and the existing Shareholders of Diponed Bio will hold 35% (thirty five percent) of the post issue share capital.

Further, Evexia would also provide Rs. 20 crores to fund the Business of the Company. The said amount shall be provided in the form of quasi capital, without interest (“Quasi Capital”) in tranches. Furthermore, Evexia can opt to convert part of the Quasi Capital, into Equity to maintain it’s 65% shareholding in the Company

Diponed Bio is engaged in the area of Research and designing innovative biological products in the fields of regenerative medicine and tissue engineering and Evexia, which is also engaged in the business of Pharmaceuticals is exploring various opportunity of expansion in the various field of pharmaceuticals either by way of establishment of new facility and/or acquisition of any existing company engaged in the area of pharmaceuticals and hence the object of acquiring 65% shareholding in Diponed Bio is based on the said policy of expansion of business of Evexia.

Earlier, the company informed it executed Term sheet with Vittal’s MediCare Private Limited to acquire 51 % stake in Vittal’s MediCare Private Limited, for INR 35 crores. Vittal’s MediCare Private Limited will become a Subsidiary Company of Evexia Lifecare Limited after completion of entire transaction as described in the Term Sheet.

Vittal’s MediCare is engaged in the business of Diagnostic Centers and hence it signifies a strategic alignment aimed at capitalizing on synergistic opportunities for business advancement.

Evexia Lifecare Ltd. (BSE: 524444) is engaged in the trading of pharmaceuticals, chemicals, manufacturing of intermediates, agricultural produce and various other products of consumer goods. It is mainly engaged in the trading of pharma chemicals. The Company in trading of various petrochemical downstream products, such as special oils, special chemicals, petroleum sulphates and solvents for industrial applications, such as rubber, leather, ink and paint industries. Its products include pharma intermediates, plastic granule, chemicals, and gold and diamond. The Company focuses to expand its line of business in Web development, software development for overseas clients, trading in gold and entertainment segment.

The company is committed to delivering high-quality products and services to its customers. It aims to achieve customer satisfaction by providing cost-effective and timely solutions. The company has a team of experienced professionals who ensure that the products meet the highest standards of quality.

Evexia Lifecare Ltd is a company that values innovation and keeps up with the latest technologies and trends in the industry. It strives to provide its customers with the best solutions and services that meet their evolving needs. The company has a long-term vision of expanding its business globally and establishing itself as a leader in the industry.